SCHEMBL1006243

SCHEMBL1006243

CC1(C)OB(c2c3ccccc3c(-c3cccc(-c4ccc5ccccc5c4)c3)c3ccccc23)OC1(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 4/20 0.58
LPL P06858 3/20 0.58
HSD17B1 P14061 1/20 0.39
HSD17B2 P37059 1/20 0.39
CHRNA1 P02708 1/20 0.38
CHRNG P07510 1/20 0.38
CHRNB1 P11230 1/20 0.38
CHRNB2 P17787 1/20 0.38
SLC6A2 P23975 1/20 0.38
CHRNB4 P30926 1/20 0.38
SLC6A4 P31645 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CHRND Q07001 1/20 0.38
ESR1 P03372 4/20 0.34
ESR2 Q92731 3/20 0.34
CYP17A1 P05093 1/20 0.34
CYP19A1 P11511 1/20 0.34
CYP11B1 P15538 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007854 0.95 LPL (0.60) LIPGLPLCHRNA1CHRNGCHRNB1
SCHEMBL29518753 0.95 LPL (0.60) LIPGLPLCHRNA1CHRNGCHRNB1
SCHEMBL22217401 0.93 LPL (0.58) LIPGLPLCHRNA1CHRNGCHRNB1
SCHEMBL22542209 0.88 LIPG (0.50) LIPGLPLESR1ESR2
SCHEMBL13855128 0.88 LIPG (0.50) LIPGLPLESR1ESR2
SCHEMBL27047505 0.86 LIPG (0.58) LIPGLPLHSD17B1HSD17B2CHRNA1
SCHEMBL13295622 0.85 LIPG (0.63) LIPGLPLHSD17B1HSD17B2CHRNA1
SCHEMBL12578322 0.84 LIPG (0.61) LIPGLPLHSD17B1HSD17B2CHRNA1
SCHEMBL13098741 0.82 LIPG (0.71) LIPGLPLGPR84IKBKB
SCHEMBL1007806 0.82 LIPG (0.76) LIPGLPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875367-B2 cyclopentaphenanthrene-based compound which is adapted for both dry and wet processes, and has excellent thermal stability and good charge transport and emission characteristics SAMSUNG MOBILE DISPLAY CO., LTD. (KR) 2011-01-25 US disclosed
US-20090230857-A1 AROMATIC HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING ORGANIC LAYER COMPRISING THE SAME AND METHOD OF MANUFACTURING THE ORGANIC LIGHT EMITTING DIODE GANGWON NATIONAL UNIVERSITY (KP) 2009-09-17 US disclosed
US-20090230857-A1 AROMATIC HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING ORGANIC LAYER COMPRISING THE SAME AND METHOD OF MANUFACTURING THE ORGANIC LIGHT EMITTING DIODE GANGWON NATIONAL UNIVERSITY (KP) 2009-09-17 US disclosed
US-20090230857-A1 AROMATIC HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING ORGANIC LAYER COMPRISING THE SAME AND METHOD OF MANUFACTURING THE ORGANIC LIGHT EMITTING DIODE GANGWON NATIONAL UNIVERSITY (KP) 2009-09-17 US disclosed
US-20080079356-A1 Organoelectroluminescent compound and organoelectroluminescent device employing the same SAMSUNG DISPLAY CO., LTD. (KR) 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080079356-A1 Organoelectroluminescent compound and organoelectroluminescent device employing the same PPOX, EML4, ALPL LIPG 696/4885LPL 1705/4885HSD17B1 1285/4885
US-20090230857-A1 AROMATIC HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING ORGANIC LAYER COMPRISING THE SAME AND METHOD OF MANUFACTURING THE ORGANIC LIGHT EMITTING DIODE CYP1A1, CYP1B1, AOX1 LIPG 3356/4885LPL 1414/4885HSD17B1 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.